It appears that AEGR is looking favorable while ISIS is looking like it won't get the nod from the FDA. That doesn't mean the panel will go that way. It still makes sense for the FDA to recommend the approval for both drugs, but with a restrictive REMS for ISIS.
What that means is much stronger market share for AEGR. So to the guy posting asking if this would be a $1B drug, it very well may be.